

12. The use of the pharmaceutical composition according to claim 11, in the manufacture of a medicament for the treatment of heart failure and peripheral arterial disease, the pharmaceutical composition further comprising one or more other additional therapeutic agents including: anti-diabetic agents, anti-hyperglycemic agents,
5 anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, anti-pancreatic agents, lipid lowering agents, anorectic
10 agents, memory enhancing agents, anti-dementia agents, cognition promoting agents, appetite suppressants, and anti-inflammatory agents.

13. The pharmaceutical composition according to claim 11, further comprising a dipeptidyl peptidase-IV inhibitor and/or a sodium-glucose transporter-2 inhibitor.
15

14. The use of a compound of any one of claims 1 to 10 in the manufacture of a medicament for the prevention, modulation or treatment of diabetes, hyperglycemia, impaired glucose tolerance, gestational diabetes, insulin resistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy, diabetic kidney disease, acute kidney injury,
20 cardiorenal syndrome, acute coronary syndrome, delayed wound healing, atherosclerosis and its sequelae, abnormal heart function, congestive heart failure, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, fatty liver disease, dislipidemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low high-density lipoprotein, high low-density lipoprotein, non-cardiac ischemia, pancreatitis, lipid
25 disorders, neurodegenerative disease, cognitive impairment, dementia, liver diseases and liver cirrhosis.

15. The use according to claim 14, wherein the compound of any one of claims 1 to 10 is to be used simultaneously, separately or sequentially with an additional therapeutic
30 agent.